$720 Million is the total value of First Light Asset Management, LLC's 73 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ELGXQ | New | ENDOLOGIX INC | $17,828,000 | – | 2,462,448 | +100.0% | 2.48% | – |
| SIBN | New | SI-BONE INC | $13,248,000 | – | 651,319 | +100.0% | 1.84% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $12,365,000 | – | 247,897 | +100.0% | 1.72% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL INC | $11,431,000 | – | 180,017 | +100.0% | 1.59% | – |
| BMY | New | BRISTOL MYERS SQUIBB CO | $7,501,000 | – | 165,397 | +100.0% | 1.04% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $3,526,000 | – | 26,920 | +100.0% | 0.49% | – |
| ARNA | New | ARENA PHARMACEUTICALS INC | $2,621,000 | – | 44,704 | +100.0% | 0.36% | – |
| EPZM | New | EPIZYME INC | $2,511,000 | – | 200,063 | +100.0% | 0.35% | – |
| PSCH | New | INVESCO SMALLCAP HEALTH CARE ETFetf | $2,038,000 | – | 17,285 | +100.0% | 0.28% | – |
| TMDX | New | TRANSMEDICS GROUP INC | $783,000 | – | 27,000 | +100.0% | 0.11% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC. | $456,000 | – | 3,000 | +100.0% | 0.06% | – |
| AGN | New | ALLERGAN PLC SHS | $361,000 | – | 2,157 | +100.0% | 0.05% | – |
| BAX | New | BAXTER INTERNATIONAL INC | $267,000 | – | 3,258 | +100.0% | 0.04% | – |
| GRFS | New | GRIFOLS SA SPONSORED ADR CLASS B | $215,000 | – | 10,166 | +100.0% | 0.03% | – |
| DHR | New | DANAHER CORP | $200,000 | – | 1,400 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.